ApollomicsAPLM
Market Cap: $15.2M
About: Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
Employees: 45
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
1.13% less ownership
Funds ownership: 10.33% [Q1] → 9.21% (-1.13%) [Q2]
17% less funds holding
Funds holding: 12 [Q1] → 10 (-2) [Q2]
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
70% less capital invested
Capital invested by funds: $6.94M [Q1] → $2.11M (-$4.83M) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for APLM.
Financial journalist opinion
Based on 3 articles about APLM published over the past 30 days